• Was a liver MRI performed using a validated methodology per institutional preference (T2* or R2* or by ferriscan [R2 MRI]) for estimation of hepatic iron content?
• Record date of liver MRI
• Does the patient have significant clinical evidence of iron overload (estimated hepatic iron content >= 10mg Fe/g liver dry weight)?
• Was a liver biopsy performed?
• Record date of liver biopsy
• Did the patient experience pulmonary hypertension during this assessment period?
• Was this a new episode of pulmonary hypertension during this assessment period?
• Did the gastroenterology/hepatology consultation and histological examination document the absence of cirrhosis, bridging fibrosis, and active hepatitis?
• Does the patient have a first-degree related HLA-haploidentical donor who is willing and able to donate bone marrow?
• Date of new episode of pulmonary hypertension
• How was pulmonary hypertension diagnosed?
• Date confirmatory typing completed
• Was an intervention required to treat pulmonary hypertension?
• Select treatment initiated
• Other, specify
• Does the patient have an HLA-matched sibling who is able and willing to donate bone marrow?
• Did the patient experience a new onset of a significant cerebrovascular event (stroke, transient ischemic attack, or seizure) during this assessment period?
• How many times did the patient experience a new onset of stroke during this assessment period?
• How many times did the patient experience a new onset of transient ischemic attack (TIA) during this assessment period?
• Has the patient experienced an uncontrolled bacterial, viral, or fungal infection in the 6 weeks before enrollment (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)?